The COVID-19 pandemic has reversed years of global progress in tackling tuberculosis and - for the first time in over a decade - TB deaths have increased. Research breakthroughs – such as new vaccines – are needed to rapidly reduce the number of new cases...
Novavax has completed its rolling submission to the World Health Organization for emergency use listing (EUL) of NVX-CoV2373, its COVID-19 vaccine candidate.
Waters Corporation and Sartorius are partnering with the aim of providing bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.
bluebird bio has signed a long-term lease for a 61,000 square foot facility at Assembly Row, Greater Boston: saying the new headquarters has been designed to reflect modern ways of working and deliver significant cost savings.
CEPI, the Coalition for Epidemic Preparedness Innovations, has announced the first funding awards under a $200m program to advance development of vaccines against SARS-CoV-2 variants and other betacoronaviruses.
Sphere Fluidics, a UK company that has developed and is commercializing single cell analysis systems underpinned by its picodroplet technology, has just closed a US$40m investment round.
Biomunex Pharmaceuticals, a French company focused on the discovery and development of bi- and multi-specific antibodies, sees its BiXAb5 project receive nearly €3m (US$3.5m) in the form of a grant from the French government.
Human papillomavirus (HPV) vaccines reduce cervical cancer rates by 87% in women who were offered the jab between the ages of 12-13, according to a study which analysed data from England's HPV vaccine program.
Clade Therapeutics has raised US$87m in a Series A led by Syncona Ltd with participation from LifeSci Venture Partners, Emerson Collective and Bristol Myers Squibb (BMS).
Lonza has been investing in developing exosome manufacturing and characterization technologies for the past five years, and this week it ramped up its focus on that category by acquiring two sites.
The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims a new report from Roots Analysis.
CPhI Worldwide will see Gerresheimer showcase its latest developments in primary packaging, drug delivery systems for newly developed biologics along with medical and diagnostic products.
A leader from Medicines for Europe will share with CPhI Worldwide attendees a look at medicine production and offer solutions for elevating the industry.
During CPhI Worldwide, leaders from two organizations will outline how CM is taking off, potential benefits, and how to clear common obstacles to adoption.
An expert from the specialty chemicals firm (and CPhI Worldwide speaker) explains trends and developments in excipients and how they drive advancements.
The global pharmaceutical industry event is returning to the real world November 9-11 this year, with online content for professionals opting not to travel.
BioNet and Sartorius’ BIA Separations are collaborating on production process development of mRNA vaccines: today announcing an optimized mRNA manufacturing process.